{
    "xml": "<topic id=\"PHP1945\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/hydroxyzine-hydrochloride\" basename=\"hydroxyzine-hydrochloride\" title=\"HYDROXYZINE HYDROCHLORIDE\">\n<title>HYDROXYZINE HYDROCHLORIDE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_321\" namespace=\"/interactions/list-of-drug-interactions/antihistamines/antihistamines-sedating/hydroxyzine\">Hydroxyzine</xref>\n</p>\n<data name=\"vtmid\">80165005</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_225690438\" title=\"Antihistamines\">Antihistamines</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\n<data name=\"secondaryDomainsOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP44256\" outputclass=\"indicationsAndDose\" rev=\"1.29\" parent=\"/drugs/hydroxyzine-hydrochloride\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Pruritus</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 1&#8211;5 years</p>\n<p>Initially 5&#8211;15&#8239;mg once daily, dose to be taken at night, increased if necessary to 50&#8239;mg daily in 3&#8211;4 divided doses.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 6&#8211;11 years</p>\n<p>Initially 15&#8211;25&#8239;mg once daily, dose to be taken at night, increased if necessary to 50&#8211;100&#8239;mg daily in 3&#8211;4 divided doses.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>Initially 25&#8239;mg once daily, dose to be taken at night, increased if necessary to 100&#8239;mg daily in 3&#8211;4 divided doses.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 25&#8239;mg daily, dose to be taken at night; increased if necessary to 25&#8239;mg 3&#8211;4 times a day.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP44217\" outputclass=\"unlicensedUse\" rev=\"1.7\" parent=\"/drugs/hydroxyzine-hydrochloride\">\n<title>Unlicensed use</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">oral</ph> use in children</p>\n<p>\n<i>Ucerax <tm tmtype=\"reg\"/>\n</i> syrup not licensed for use in children under 1 year.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP44284\" outputclass=\"importantSafetyInformation\" rev=\"1.24\" parent=\"/drugs/hydroxyzine-hydrochloride\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">In adults</p>\n<p outputclass=\"title\">Hydroxyzine: risk of QT-interval prolongation and Torsade de Pointes (April 2015)</p>\n<p>Following concerns of heart rhythm abnormalities, the safety and efficacy of hydroxyzine has been reviewed by the European Medicines Agency. The review concludes that hydroxyzine is associated with a small risk of QT-interval prolongation and Torsade de Pointes; these events are most likely to occur in patients who have risk factors for QT prolongation, e.g. concomitant use of drugs that prolong the QT interval, cardiovascular disease, family history of sudden cardiac death, significant electrolyte imbalance (low plasma-potassium or plasma-magnesium concentrations), or significant bradycardia.</p>\n<p>To minimise the risk of such adverse effects, the following dose restrictions have been made and new cautions and contra-indications added:</p>\n<ul>\n<li>Hydroxyzine is contra-indicated in patients with prolonged QT- interval or who have risk factors for QT-interval prolongation;</li>\n<li>Avoid use in the elderly due to increased susceptibility to the side-effects of hydroxyzine;</li>\n<li>Consider the risks of QT-interval prolongation and Torsade de Pointes before prescribing to patients taking drugs that lower heart rate or plasma-potassium concentration;</li>\n<li>In adults, the maximum daily dose is 100&#8239;mg;</li>\n<li>In the elderly, the maximum daily dose is 50&#8239;mg (if use of hydroxyzine cannot be avoided);</li>\n<li>The lowest effective dose for the shortest period of time should be prescribed.</li>\n</ul>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">In children</p>\n<p outputclass=\"title\">Hydroxyzine: risk of QT-interval prolongation and Torsade de Pointes (April 2015)</p>\n<p>Following concerns of heart rhythm abnormalities, the safety and efficacy of hydroxyzine has been reviewed by the European Medicines Agency. The review concludes that hydroxyzine is associated with a small risk of QT-interval prolongation and Torsade de Pointes; these events are most likely to occur in patients who have risk factors for QT prolongation, e.g. concomitant use of drugs that prolong the QT interval, cardiovascular disease, family history of sudden cardiac death, significant electrolyte imbalance (low plasma-potassium or plasma-magnesium concentrations), or significant bradycardia.</p>\n<p>To minimise the risk of such adverse effects, the following dose restrictions have been made and new cautions and contra-indications added:</p>\n<ul>\n<li>Hydroxyzine is contra-indicated in patients with prolonged QT- interval or who have risk factors for QT-interval prolongation;</li>\n<li>Consider the risks of QT-interval prolongation and Torsade de Pointes before prescribing to patients taking drugs that lower heart rate or plasma-potassium concentration;</li>\n<li>In children with body-weight up to 40&#8239;kg, the maximum daily dose is 2&#8239;mg/kg;</li>\n<li>The lowest effective dose for the shortest period of time should be prescribed.</li>\n</ul>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP44287\" outputclass=\"contraindications\" rev=\"1.20\" parent=\"/drugs/hydroxyzine-hydrochloride\">\n<title>Contra-indications</title>\n<body>\r\n<section outputclass=\"contraindications\">\r\n<p>\r\n<ph outputclass=\"contraindication\">Avoid in <xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref> (some antihistamines are thought to be safe)</ph>; <ph outputclass=\"contraindication\">neonate (due to significant antimuscarinic activity)</ph> (in neonates)</p>\r\n </section>\r\n\r\n\r\n\r\n\r\n\r\n\r\n</body>\n</topic>\n<topic id=\"PHP44316\" outputclass=\"cautions\" rev=\"1.13\" parent=\"/drugs/hydroxyzine-hydrochloride\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Epilepsy</ph>; <ph outputclass=\"caution\">prostatic hypertrophy</ph> (in adults); <ph outputclass=\"caution\">pyloroduodenal obstruction</ph>; <ph outputclass=\"caution\">susceptibility to angle-closure glaucoma</ph>; <ph outputclass=\"caution\">susceptibility to QT interval prolongation</ph>; <ph outputclass=\"caution\">urinary retention</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP44253\" outputclass=\"interactions\" rev=\"1.11\" parent=\"/drugs/hydroxyzine-hydrochloride\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (antihistamines).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP44228\" outputclass=\"sideEffects\" rev=\"1.21\" parent=\"/drugs/hydroxyzine-hydrochloride\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Anaphylaxis</ph>; <ph outputclass=\"sideEffect\">angioedema</ph>; <ph outputclass=\"sideEffect\">angle-closure glaucoma</ph>; <ph outputclass=\"sideEffect\">arrhythmias</ph>; <ph outputclass=\"sideEffect\">blood disorders</ph>; <ph outputclass=\"sideEffect\">bronchospasm</ph>; <ph outputclass=\"sideEffect\">confusion</ph>; <ph outputclass=\"sideEffect\">convulsions</ph>; <ph outputclass=\"sideEffect\">depression</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">extrapyramidal effects</ph>; <ph outputclass=\"sideEffect\">hypersensitivity reactions</ph>; <ph outputclass=\"sideEffect\">hypotension</ph>; <ph outputclass=\"sideEffect\">liver dysfunction</ph>; <ph outputclass=\"sideEffect\">palpitation</ph>; <ph outputclass=\"sideEffect\">photosensitivity reactions</ph>; <ph outputclass=\"sideEffect\">rashes</ph>; <ph outputclass=\"sideEffect\">sleep disturbances</ph>; <ph outputclass=\"sideEffect\">tremor</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Antimuscarinic effects</ph>; <ph outputclass=\"sideEffect\">blurred vision</ph>; <ph outputclass=\"sideEffect\">drowsiness</ph>; <ph outputclass=\"sideEffect\">dry mouth</ph>; <ph outputclass=\"sideEffect\">gastro-intestinal disturbances</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">psychomotor impairment</ph>; <ph outputclass=\"sideEffect\">urinary retention</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"specificity\">In adults</p>\n<p>Elderly patients are more susceptible to side-effects.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">In children</p>\n<p>Children are more susceptible to side-effects.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">In adults</p>\n<p>Drowsiness is a significant side-effect with most of the older antihistamines although paradoxical stimulation may occur rarely, especially with high doses or in children and the elderly. Drowsiness may diminish after a few days of treatment and is considerably less of a problem with the newer antihistamines.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">In children</p>\n<p>Drowsiness is a significant side-effect with most of the older antihistamines although paradoxical stimulation may occur rarely in children, especially with high doses. Drowsiness may diminish after a few days of treatment and is considerably less of a problem with the newer antihistamines.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP44246\" outputclass=\"pregnancy\" parent=\"/drugs/hydroxyzine-hydrochloride\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Most manufacturers of antihistamines advise avoiding their use during pregnancy; toxicity in <i>animal</i> studies with higher doses.</p>\n<p>Use in the latter part of the third trimester may cause adverse effects in neonates such as irritability, paradoxical excitability, and tremor.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP44327\" outputclass=\"breastFeeding\" parent=\"/drugs/hydroxyzine-hydrochloride\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid.</p>\n<p>Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP44268\" outputclass=\"hepaticImpairment\" parent=\"/drugs/hydroxyzine-hydrochloride\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Reduce daily dose by one-third.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid in severe liver disease&#8212;increased risk of coma.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP44235\" outputclass=\"renalImpairment\" parent=\"/drugs/hydroxyzine-hydrochloride\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Reduce daily dose by half.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP44238\" outputclass=\"patientAndCarerAdvice\" rev=\"1.13\" parent=\"/drugs/hydroxyzine-hydrochloride\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"adviceAroundDrivingAndOtherTasks\">\n<title>Driving and skilled tasks</title>\n<sectiondiv>\n<p>Drowsiness may affect performance of skilled tasks (e.g. cycling or driving); sedating effects enhanced by alcohol.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP1945-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/hydroxyzine-hydrochloride\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral solution, oral suspension</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75864\" title=\"Tablet\" namespace=\"/drugs/hydroxyzine-hydrochloride/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75879\" title=\"Oral solution\" namespace=\"/drugs/hydroxyzine-hydrochloride/oral-solution\">Oral solution</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP107699\" namespace=\"/about/changes\" title=\"Changes\" count=\"1\" rel=\"backlink\">Changes</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78112\" namespace=\"/treatment-summaries/hypnotics-and-anxiolytics\" title=\"Hypnotics and anxiolytics\" count=\"1\" rel=\"backlink\">Hypnotics and anxiolytics</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_321\" namespace=\"/interactions/list-of-drug-interactions/antihistamines/antihistamines-sedating/hydroxyzine\" title=\"Hydroxyzine\" count=\"1\" rel=\"link\">Hydroxyzine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78608\" namespace=\"/treatment-summaries/acute-porphyrias\" title=\"Acute porphyrias\" count=\"1\" rel=\"link\">Acute porphyrias</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75864\" namespace=\"/drugs/hydroxyzine-hydrochloride/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75879\" namespace=\"/drugs/hydroxyzine-hydrochloride/oral-solution\" title=\"Oral solution\" count=\"1\" rel=\"link\">Oral solution</xref>\n</links>\n</topic>",
    "id": "PHP1945",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/hydroxyzine-hydrochloride",
    "basename": "hydroxyzine-hydrochloride",
    "title": "HYDROXYZINE HYDROCHLORIDE",
    "interactants": [
        {
            "id": "bnf_int_321",
            "label": "Hydroxyzine"
        }
    ],
    "vtmid": "80165005",
    "drugClassification": [
        "Antihistamines"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "secondaryDomainsOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Pruritus",
                        "html": "Pruritus"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "child": [
                    {
                        "textContent": "Initially 5&#8211;15 mg once daily, dose to be taken at night, increased if necessary to 50 mg daily in 3&#8211;4 divided doses.",
                        "html": "<p>Initially 5&#8211;15&#8239;mg once daily, dose to be taken at night, increased if necessary to 50&#8239;mg daily in 3&#8211;4 divided doses.</p>",
                        "ageGroup": "1&#8211;5 years"
                    },
                    {
                        "textContent": "Initially 15&#8211;25 mg once daily, dose to be taken at night, increased if necessary to 50&#8211;100 mg daily in 3&#8211;4 divided doses.",
                        "html": "<p>Initially 15&#8211;25&#8239;mg once daily, dose to be taken at night, increased if necessary to 50&#8211;100&#8239;mg daily in 3&#8211;4 divided doses.</p>",
                        "ageGroup": "6&#8211;11 years"
                    },
                    {
                        "textContent": "Initially 25 mg once daily, dose to be taken at night, increased if necessary to 100 mg daily in 3&#8211;4 divided doses.",
                        "html": "<p>Initially 25&#8239;mg once daily, dose to be taken at night, increased if necessary to 100&#8239;mg daily in 3&#8211;4 divided doses.</p>",
                        "ageGroup": "12&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "Initially 25 mg daily, dose to be taken at night; increased if necessary to 25 mg 3&#8211;4 times a day.",
                        "html": "<p>Initially 25&#8239;mg daily, dose to be taken at night; increased if necessary to 25&#8239;mg 3&#8211;4 times a day.</p>"
                    }
                ]
            }
        ]
    },
    "unlicensedUse": {
        "unlicensedUse": [
            {
                "type": "unlicensedUse",
                "specificity": {
                    "textContent": "With oral use in children",
                    "html": "With <ph outputclass=\"route\">oral</ph> use in children",
                    "patientType": "children",
                    "routes": [
                        "oral"
                    ]
                },
                "textContent": "Ucerax syrup not licensed for use in children under 1 year.",
                "html": "<p>\n<i>Ucerax <tm tmtype=\"reg\"/>\n</i> syrup not licensed for use in children under 1 year.</p>"
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "specificity": {
                    "textContent": "In adults",
                    "html": "In adults",
                    "patientType": "adults"
                },
                "title": "Hydroxyzine: risk of QT-interval prolongation and Torsade de Pointes (April 2015)",
                "textContent": "Following concerns of heart rhythm abnormalities, the safety and efficacy of hydroxyzine has been reviewed by the European Medicines Agency. The review concludes that hydroxyzine is associated with a small risk of QT-interval prolongation and Torsade de Pointes; these events are most likely to occur in patients who have risk factors for QT prolongation, e.g. concomitant use of drugs that prolong the QT interval, cardiovascular disease, family history of sudden cardiac death, significant electrolyte imbalance (low plasma-potassium or plasma-magnesium concentrations), or significant bradycardia.\n\nTo minimise the risk of such adverse effects, the following dose restrictions have been made and new cautions and contra-indications added:\n\nHydroxyzine is contra-indicated in patients with prolonged QT- interval or who have risk factors for QT-interval prolongation; Avoid use in the elderly due to increased susceptibility to the side-effects of hydroxyzine; Consider the risks of QT-interval prolongation and Torsade de Pointes before prescribing to patients taking drugs that lower heart rate or plasma-potassium concentration; In adults, the maximum daily dose is 100 mg; In the elderly, the maximum daily dose is 50 mg (if use of hydroxyzine cannot be avoided); The lowest effective dose for the shortest period of time should be prescribed.",
                "html": "<p>Following concerns of heart rhythm abnormalities, the safety and efficacy of hydroxyzine has been reviewed by the European Medicines Agency. The review concludes that hydroxyzine is associated with a small risk of QT-interval prolongation and Torsade de Pointes; these events are most likely to occur in patients who have risk factors for QT prolongation, e.g. concomitant use of drugs that prolong the QT interval, cardiovascular disease, family history of sudden cardiac death, significant electrolyte imbalance (low plasma-potassium or plasma-magnesium concentrations), or significant bradycardia.</p><p>To minimise the risk of such adverse effects, the following dose restrictions have been made and new cautions and contra-indications added:</p><ul>\n<li>Hydroxyzine is contra-indicated in patients with prolonged QT- interval or who have risk factors for QT-interval prolongation;</li>\n<li>Avoid use in the elderly due to increased susceptibility to the side-effects of hydroxyzine;</li>\n<li>Consider the risks of QT-interval prolongation and Torsade de Pointes before prescribing to patients taking drugs that lower heart rate or plasma-potassium concentration;</li>\n<li>In adults, the maximum daily dose is 100&#8239;mg;</li>\n<li>In the elderly, the maximum daily dose is 50&#8239;mg (if use of hydroxyzine cannot be avoided);</li>\n<li>The lowest effective dose for the shortest period of time should be prescribed.</li>\n</ul>"
            },
            {
                "type": "importantSafetyInformation",
                "specificity": {
                    "textContent": "In children",
                    "html": "In children",
                    "patientType": "children"
                },
                "title": "Hydroxyzine: risk of QT-interval prolongation and Torsade de Pointes (April 2015)",
                "textContent": "Following concerns of heart rhythm abnormalities, the safety and efficacy of hydroxyzine has been reviewed by the European Medicines Agency. The review concludes that hydroxyzine is associated with a small risk of QT-interval prolongation and Torsade de Pointes; these events are most likely to occur in patients who have risk factors for QT prolongation, e.g. concomitant use of drugs that prolong the QT interval, cardiovascular disease, family history of sudden cardiac death, significant electrolyte imbalance (low plasma-potassium or plasma-magnesium concentrations), or significant bradycardia.\n\nTo minimise the risk of such adverse effects, the following dose restrictions have been made and new cautions and contra-indications added:\n\nHydroxyzine is contra-indicated in patients with prolonged QT- interval or who have risk factors for QT-interval prolongation; Consider the risks of QT-interval prolongation and Torsade de Pointes before prescribing to patients taking drugs that lower heart rate or plasma-potassium concentration; In children with body-weight up to 40 kg, the maximum daily dose is 2 mg/kg; The lowest effective dose for the shortest period of time should be prescribed.",
                "html": "<p>Following concerns of heart rhythm abnormalities, the safety and efficacy of hydroxyzine has been reviewed by the European Medicines Agency. The review concludes that hydroxyzine is associated with a small risk of QT-interval prolongation and Torsade de Pointes; these events are most likely to occur in patients who have risk factors for QT prolongation, e.g. concomitant use of drugs that prolong the QT interval, cardiovascular disease, family history of sudden cardiac death, significant electrolyte imbalance (low plasma-potassium or plasma-magnesium concentrations), or significant bradycardia.</p><p>To minimise the risk of such adverse effects, the following dose restrictions have been made and new cautions and contra-indications added:</p><ul>\n<li>Hydroxyzine is contra-indicated in patients with prolonged QT- interval or who have risk factors for QT-interval prolongation;</li>\n<li>Consider the risks of QT-interval prolongation and Torsade de Pointes before prescribing to patients taking drugs that lower heart rate or plasma-potassium concentration;</li>\n<li>In children with body-weight up to 40&#8239;kg, the maximum daily dose is 2&#8239;mg/kg;</li>\n<li>The lowest effective dose for the shortest period of time should be prescribed.</li>\n</ul>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Avoid in Acute porphyrias (some antihistamines are thought to be safe)",
                "html": "Avoid in <xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref> (some antihistamines are thought to be safe)",
                "references": [
                    {
                        "id": "PHP78608",
                        "label": "Acute porphyrias"
                    }
                ]
            },
            {
                "type": "contraindications",
                "textContent": "neonate (due to significant antimuscarinic activity) in neonates",
                "html": "neonate (due to significant antimuscarinic activity) in neonates",
                "specificity": {
                    "patientType": "neonates"
                }
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Epilepsy",
                "html": "Epilepsy"
            },
            {
                "type": "cautions",
                "textContent": "prostatic hypertrophy in adults",
                "html": "prostatic hypertrophy in adults",
                "specificity": {
                    "patientType": "adults"
                }
            },
            {
                "type": "cautions",
                "textContent": "pyloroduodenal obstruction",
                "html": "pyloroduodenal obstruction"
            },
            {
                "type": "cautions",
                "textContent": "susceptibility to angle-closure glaucoma",
                "html": "susceptibility to angle-closure glaucoma"
            },
            {
                "type": "cautions",
                "textContent": "susceptibility to QT interval prolongation",
                "html": "susceptibility to QT interval prolongation"
            },
            {
                "type": "cautions",
                "textContent": "urinary retention",
                "html": "urinary retention"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (antihistamines).",
                "html": "<p>Appendix 1 (antihistamines).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Anaphylaxis",
                        "html": "Anaphylaxis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "angioedema",
                        "html": "angioedema",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "angle-closure glaucoma",
                        "html": "angle-closure glaucoma",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "arrhythmias",
                        "html": "arrhythmias",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "blood disorders",
                        "html": "blood disorders",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "bronchospasm",
                        "html": "bronchospasm",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "confusion",
                        "html": "confusion",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "convulsions",
                        "html": "convulsions",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "depression",
                        "html": "depression",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "extrapyramidal effects",
                        "html": "extrapyramidal effects",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "hypersensitivity reactions",
                        "html": "hypersensitivity reactions",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "hypotension",
                        "html": "hypotension",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "liver dysfunction",
                        "html": "liver dysfunction",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "palpitation",
                        "html": "palpitation",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "photosensitivity reactions",
                        "html": "photosensitivity reactions",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "rashes",
                        "html": "rashes",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "sleep disturbances",
                        "html": "sleep disturbances",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "tremor",
                        "html": "tremor",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Antimuscarinic effects",
                        "html": "Antimuscarinic effects",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "blurred vision",
                        "html": "blurred vision",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "drowsiness",
                        "html": "drowsiness",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "dry mouth",
                        "html": "dry mouth",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "gastro-intestinal disturbances",
                        "html": "gastro-intestinal disturbances",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "psychomotor impairment",
                        "html": "psychomotor impairment",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "urinary retention",
                        "html": "urinary retention",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "specificity": {
                    "textContent": "In adults",
                    "html": "In adults",
                    "patientType": "adults"
                },
                "textContent": "Elderly patients are more susceptible to side-effects.",
                "html": "<p>Elderly patients are more susceptible to side-effects.</p>"
            },
            {
                "type": "advice",
                "specificity": {
                    "textContent": "In children",
                    "html": "In children",
                    "patientType": "children"
                },
                "textContent": "Children are more susceptible to side-effects.",
                "html": "<p>Children are more susceptible to side-effects.</p>"
            },
            {
                "type": "advice",
                "specificity": {
                    "textContent": "In adults",
                    "html": "In adults",
                    "patientType": "adults"
                },
                "textContent": "Drowsiness is a significant side-effect with most of the older antihistamines although paradoxical stimulation may occur rarely, especially with high doses or in children and the elderly. Drowsiness may diminish after a few days of treatment and is considerably less of a problem with the newer antihistamines.",
                "html": "<p>Drowsiness is a significant side-effect with most of the older antihistamines although paradoxical stimulation may occur rarely, especially with high doses or in children and the elderly. Drowsiness may diminish after a few days of treatment and is considerably less of a problem with the newer antihistamines.</p>"
            },
            {
                "type": "advice",
                "specificity": {
                    "textContent": "In children",
                    "html": "In children",
                    "patientType": "children"
                },
                "textContent": "Drowsiness is a significant side-effect with most of the older antihistamines although paradoxical stimulation may occur rarely in children, especially with high doses. Drowsiness may diminish after a few days of treatment and is considerably less of a problem with the newer antihistamines.",
                "html": "<p>Drowsiness is a significant side-effect with most of the older antihistamines although paradoxical stimulation may occur rarely in children, especially with high doses. Drowsiness may diminish after a few days of treatment and is considerably less of a problem with the newer antihistamines.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Most manufacturers of antihistamines advise avoiding their use during pregnancy; toxicity in animal studies with higher doses.\n\nUse in the latter part of the third trimester may cause adverse effects in neonates such as irritability, paradoxical excitability, and tremor.",
                "html": "<p>Most manufacturers of antihistamines advise avoiding their use during pregnancy; toxicity in <i>animal</i> studies with higher doses.</p><p>Use in the latter part of the third trimester may cause adverse effects in neonates such as irritability, paradoxical excitability, and tremor.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid.\n\nMost antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.",
                "html": "<p>Manufacturer advises avoid.</p><p>Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Reduce daily dose by one-third.",
                "html": "<p>Reduce daily dose by one-third.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid in severe liver disease&#8212;increased risk of coma.",
                "html": "<p>Avoid in severe liver disease&#8212;increased risk of coma.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Reduce daily dose by half.",
                "html": "<p>Reduce daily dose by half.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "adviceAroundDrivingAndOtherTasks": [
            {
                "type": "adviceAroundDrivingAndOtherTasks",
                "textContent": "Drowsiness may affect performance of skilled tasks (e.g. cycling or driving); sedating effects enhanced by alcohol.",
                "html": "<p>Drowsiness may affect performance of skilled tasks (e.g. cycling or driving); sedating effects enhanced by alcohol.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral solution",
                "oral suspension"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75864",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75879",
                "label": "Oral solution",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "treatmentSummary": [
            {
                "id": "PHP107699",
                "label": "Changes",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78112",
                "label": "Hypnotics and anxiolytics",
                "type": "treatmentSummary"
            }
        ],
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_321",
                "label": "Hydroxyzine",
                "type": "interaction"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78608",
                "label": "Acute porphyrias",
                "type": "treatmentSummary"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75864",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75879",
                "label": "Oral solution",
                "type": "medicinalForm"
            }
        ]
    }
}